(Please click on Link to View Press Reslease)
ACP-501 (rhLCAT) Phase 1 initiation press release March 30 2012
AlphaCore Pharma Initiates ACP-501 (rhLCAT) Clinical Trial in Patients with Coronary Heart Disease
March 30th, 2012
Tel: 734.527.9137
Latest News
- 04/03/2013 MedImmune, Astra Zeneca's Biologics Arm, Acquires AlphaCore Pharma
- 12/10/2012 NIH BrIDGs Program to Support Development of ACP-501 for Treatment of Familial LCAT Deficiency
- 11/02/2012 AlphaCore Granted Orphan Drug Designation for ACP-501 (rhLCAT) by European Medicines Agency
- 10/09/2012 AlphaCore Reports Positive Phase 1 Results for ACP-501 (rhLCAT) in Patients with Stable Atherosclerosis
© Copyright 2013 AlphaCore Pharma